Shweta P. Kamat

Mumbai, MH, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022.

In vitro activity of aztreonam-avibactam and comparators against Enterobacterales isolated from bloodstream infections: ATLAS/ surveillance, 2021-2022.

Journal: Microbiology spectrum

Published: June 30, 2026

The in vitro activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used in vitro diagnostic kits.

The in vitro activity of aztreonam-avibactam and cefiderocol against globally collected clinical metallo-β-lactamase- and/or serine-carbapenemase-positive Enterobacterales isolates and the utility of commonly used in vitro diagnostic kits.

Journal: Microbiology spectrum

Published: March 31, 2026

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022).

In vitro activity of aztreonam/avibactam and comparators against Enterobacterales isolates from patients with hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated intra-abdominal infections (ATLAS, 2021-2022).

Journal: The Journal of antimicrobial chemotherapy

Published: December 08, 2025

Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial.

Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: October 24, 2024

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis.

Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis.

Journal: Cureus

Published: September 26, 2024

Correction to: Ceftazidime‑Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta‑analysis.

Correction to: Ceftazidime‑Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta‑analysis.

Journal: Infectious diseases and therapy

Published: August 28, 2024

Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.

Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018-2022.

Journal: Journal of global antimicrobial resistance

Published: February 28, 2024

Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.

Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.

Journal: Infectious diseases and therapy

Published: November 15, 2023

In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.

In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: May 18, 2023

Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016-2020 Compared to 2011-2015: Results From the ATLAS Surveillance Study.

Antimicrobial Susceptibility Among Gram-Negative Isolates in Pediatric Patients in Latin America, Africa-Middle East, and Asia From 2016-2020 Compared to 2011-2015: Results From the ATLAS Surveillance Study.

Journal: Journal of the Pediatric Infectious Diseases Society

Published: January 27, 2023

In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.

In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.

Journal: Diagnostic microbiology and infectious disease

Published: September 16, 2021

Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.

Ceftazidime-avibactam plus metronidazole vs. meropenem in complicated intra-abdominal infections: Indian subset from RECLAIM.

Journal: Journal of infection in developing countries

Published: February 16, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026